Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI Resistance

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

114

Participants

Timeline

Start Date

October 8, 2019

Primary Completion Date

October 31, 2024

Study Completion Date

February 28, 2025

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

Durvalumab (MEDI4736)

"1500 mg, every 4 weeks. CxD1 for each cycle, 1 cycle = 28 days~EXCEPT FOR CYCLE 1 IN ARM C : at C1D8 and cycle 1 = 35 days~c=cycle D= day"

DRUG

Monalizumab (IPH2201)

"1500 mg, every 4 weeks. CXD1 for each cycle, 1 cycle = 28 days~c=cycle D= day"

DRUG

Oleclumab (MEDI9447)

"3000 mg every 2 week x 4 doses, followed by 3000 mg every 4 weeks. C1D1, C1D15, C2D1, C2D15 and CXD1 for the orther cycles, 1 cycle = 28 days.~c=cycle D= day"

DRUG

Ceralasertib (AZD6738)

"240 mg bid in Cycle 1, Days 1-7, followed by 7 days on treatment in each cycle between Days 22 and 28.~CxD22-D28 for each cycle, 1 cycle = 28 days EXCEPT FOR CYCLE 1 : at C1D1,C1D29 and cycle 1 = 35 days~c=cycle D= day"

DRUG

DOCETAXEL

"75 mg/m2, every 3 weeks. CxD1 for each cycle, 1 cycle = 21 days~c=cycle D= day"

DRUG

Savolitinib

"600 mg QD~1 cycle = 28 days"

Trial Locations (1)

13354

Assistance Publique Hopitaux de Marseille, Marseille

All Listed Sponsors
lead

Assistance Publique Hopitaux De Marseille

OTHER